Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1931 1
1975 2
1978 1
1981 1
1984 1
1985 1
1986 3
1987 3
1988 7
1989 4
1990 4
1991 11
1992 5
1993 12
1994 13
1995 9
1996 7
1997 9
1998 10
1999 8
2000 10
2001 14
2002 16
2003 21
2004 23
2005 24
2006 20
2007 23
2008 37
2009 28
2010 17
2011 23
2012 36
2013 40
2014 37
2015 53
2016 43
2017 55
2018 54
2019 50
2020 64
2021 58
2022 24
Text availability
Article attribute
Article type
Publication date

Search Results

784 results
Results by year
Filters applied: . Clear all
Page 1
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. Kalinsky K, et al. Among authors: chia skl. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1. N Engl J Med. 2021. PMID: 34914339 Free PMC article. Clinical Trial.
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M; ExteNET Study Group. Chan A, et al. Among authors: chia s. Clin Breast Cancer. 2021 Feb;21(1):80-91.e7. doi: 10.1016/j.clbc.2020.09.014. Epub 2020 Oct 6. Clin Breast Cancer. 2021. PMID: 33183970 Free article. Clinical Trial.
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G. Slamon DJ, et al. Among authors: chia s. J Clin Oncol. 2018 Aug 20;36(24):2465-2472. doi: 10.1200/JCO.2018.78.9909. Epub 2018 Jun 3. J Clin Oncol. 2018. PMID: 29860922 Clinical Trial.
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Schneeweiss A, et al. Among authors: chia s. Ann Oncol. 2013 Sep;24(9):2278-84. doi: 10.1093/annonc/mdt182. Epub 2013 May 22. Ann Oncol. 2013. PMID: 23704196 Free article. Clinical Trial.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G. Slamon DJ, et al. Among authors: chia s. N Engl J Med. 2020 Feb 6;382(6):514-524. doi: 10.1056/NEJMoa1911149. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31826360 Clinical Trial.
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA. Slamon DJ, et al. Among authors: chia s. Ann Oncol. 2021 Aug;32(8):1015-1024. doi: 10.1016/j.annonc.2021.05.353. Epub 2021 Jun 5. Ann Oncol. 2021. PMID: 34102253 Free article. Clinical Trial.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Rugo HS, et al. Among authors: chia s. Lancet Oncol. 2021 Apr;22(4):489-498. doi: 10.1016/S1470-2045(21)00034-6. Lancet Oncol. 2021. PMID: 33794206 Clinical Trial.
The RNA-binding protein HuR is a negative regulator in adipogenesis.
Siang DTC, Lim YC, Kyaw AMM, Win KN, Chia SY, Degirmenci U, Hu X, Tan BC, Walet ACE, Sun L, Xu D. Siang DTC, et al. Among authors: chia sy. Nat Commun. 2020 Jan 10;11(1):213. doi: 10.1038/s41467-019-14001-8. Nat Commun. 2020. PMID: 31924774 Free PMC article.
COVID-19 and older people in Asia: Asian Working Group for Sarcopenia calls to actions.
Lim WS, Liang CK, Assantachai P, Auyeung TW, Kang L, Lee WJ, Lim JY, Sugimoto K, Akishita M, Chia SL, Chou MY, Ding YY, Iijima K, Jang HC, Kawashima S, Kim M, Kojima T, Kuzuya M, Lee J, Lee SY, Lee Y, Peng LN, Wang NY, Wang YW, Won CW, Woo J, Chen LK, Arai H. Lim WS, et al. Among authors: chia sl. Geriatr Gerontol Int. 2020 Jun;20(6):547-558. doi: 10.1111/ggi.13939. Geriatr Gerontol Int. 2020. PMID: 32365259 Free PMC article. Review.
784 results